November 12, 2020
Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum

July 24, 2020
Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research

June 03, 2020
KRLD Radio Interview: Some Covid Survivors Face Long-Term Consequences

May 20, 2020
Why Overcoming Covid-19 is Just the First Hurdle of a Much Longer Journey: Irreversible Lung Scarring Possible in Survivors

June 01, 2020
Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease

April 09, 2020
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution